Table 1 Characteristics of RA patients for whom analysis of IL-17-positive CD4 T cells in paired blood and synovial fluid (top), and paired blood and synovium (bottom) was performed.

1

+ve

+ve

<1

MTX,

HCQ

N

N

39

15

6.20

1.95

2.52

2

+ve

+ve

2

MTX, HCQ

N

N

61

8

7.01

1.09

0.82

3

+ve

+ve

1

N

N

N

21

7

4.18

2.36

2.17

4

+ve

-ve

23

MTX

N

N

18

11

5.83

0.73

0.79

5

+ve

-ve

45

MTX

N

N

60

11

5.27

0.63

0.53

6

+ve

+ve

5

MTX, SSZ

N

N

69

93

5.48

2.34

2.84

7

+ve

+ve

4

N

Y

Y

28

30

3.51

3.48

1.17

8

+ve

+ve

<1

MTX,

HCQ

N

Y

63

72

6.14

1.59

1.44

9

+ve

+ve

5

N

Y

Y

32

12

5.62

1.30

7.90

10

+ve

+ve

<1

MTX

Y

N

80

71

6.08

0.73

5.18

11

-ve

+ve

1

N

N

N

10

15

5.76

0.86

3.48

12

+ve

+ve

5

MTX

Y

Y

24

24

4.42

1.06

1.06

13

-ve

-ve

6

HCQ

N

N

81

92

4.39

0.37

4.45

14

+ve

+ve

1

MTX

N

Y

17

16

4.48

0.49

0.46

Treatment

% CD3+CD4+

IL17+

Subject

RF

ACPA

Disease duration, years

DMARD

Anti-TNF

Steroid

ESR,

mm/hr

CRP,

mg/l

DAS28

(ESR)

PBMC

1

+ve

+ve

16

N

Y

N

20

20

3.83

0.77

0.55

2

+ve

+ve

4

N

Y

Y

13

9

4.95

0.57

0.48

3

+ve

+ve

5

N

Y

Y

13

3

4.50

1.63

0.78

4

-ve

+ve

8

MTX

Y

N

12

0

3.57

1.49

1.08

5

+ve

+ve

20

N

N

Y

89

24

6.03

2.63

0.91

6

+ve

+ve

23

N

N

Y

45

57

5.86

0.08

0.24

7

+ve

+ve

20

SSZ

N

N

31

11

4.33

0.73

0.81

8

+ve

+ve

5

N

Y

Y

15

3

4.55

0.29

1.17

9

-ve

-ve

15

N

Y

N

115

22

6.19

1.37

0.99

10

-ve

+ve

1

LEF

N

N

10

15

5.76

1.65